Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series.

摘要: We intended to assess safety, response treatment and time of 1.25 mg/kg oral S-ketamine as add-on standard antidepressants in four depressed patients. Two patients with melancholic depression responded early stayed remission, while two distinct somatic symptoms, chronicity or atypical features did not respond. The limited number does allow conclusions about efficacy. Oral was well tolerated could merit being studied randomised controlled trials due its higher practicability compared (S-)ketamine infusion therapy. Clinical subtyping should be considered.